ReCode Therapeutics Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Employees
  • 41
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $80M
Latest Deal Amount
  • Investors
  • 14

ReCode Therapeutics General Information

Description

Developer of biopharmaceutical technology intended to address the correction of the nonsense mutations. The company's technology develops a suppressor tRNA delivery to treat nonsense mutations, helping lung cells to override premature stop signals and make full-length, functional CFTR protein, enabling patients to avail medicines for genetic respiratory diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Primary Office
  • 1455 Adams Drive
  • Suite 1120
  • Menlo Park, CA 94025
  • United States
+1 (408) 000-0000

ReCode Therapeutics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ReCode Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series B) 21-Oct-2021 $80M 00000 00000 Completed Generating Revenue
2. Later Stage VC (Series A1) 26-Mar-2020 0000 0000 00000 Completed Generating Revenue
1. Early Stage VC (Series A2) 08-Feb-2019 $2M $2M 0000 Completed Generating Revenue
To view ReCode Therapeutics’s complete valuation and funding history, request access »

ReCode Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A-5 0,000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series A-4 0,000,000 00.000000 00 00.0 00.0 00 00.0 0.00
Series A-3 0,000,000 00.000000 00 000.00 000.00 00 000.00 0.000
Series A-2 1,126,512 $0.000100 5% $1.85 $1.85 1x $1.85 2.8%
Series A-1 14,296,176 $0.000100 5% $5.6 $5.6 1x $5.6 35.48%
To view ReCode Therapeutics’s complete cap table history, request access »

ReCode Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of biopharmaceutical technology intended to address the correction of the nonsense mutations. The company's te
Drug Delivery
Menlo Park, CA
41 As of 2021
00000
0000 0000-00-00
00000000000 00000

000000

citation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehend
0000000000000
Monrovia, CA
000 As of 0000
00000
0000 0000-00-00
00000000 00000

00000000

dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui o
0000000000000
Warrington, PA
00 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ReCode Therapeutics Competitors (29)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Xencor Formerly VC-backed Monrovia, CA 000 00000 00000000 00000
00000000 000000000 Corporate Backed or Acquired Warrington, PA 00 00000 00000000 00000
000000000 Formerly VC-backed Tucson, AZ 00 000.00 000000&0 000.00
0000 0000000000000 Venture Capital-Backed Helsinki, Finland 00 000.00 0000000000 0 000.00
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
You’re viewing 5 of 29 competitors. Get the full list »

ReCode Therapeutics Executive Team (11)

Name Title Board Seat Contact Info
David Lockhart Ph.D Chief Executive Officer, President and Board Member
Mukul Agarwal Chief Business Officer
Philip Thomas Ph.D Co-Founder & Advisor
Daniel Siegwart Ph.D Co-Founder, Advisor and Collaborator
Angèle Maki Ph.D Senior Vice President & Head, Business Development
You’re viewing 5 of 11 executive team members. Get the full list »

ReCode Therapeutics Board Members (8)

Name Representing Role Since
Edward Hurwitz ReCode Therapeutics Board Member 000 0000
Helen Kim ReCode Therapeutics Board Member 000 0000
Michael Torres Ph.D ReCode Therapeutics Co-Founder, Vice President of Research & Development, Texas Site & Board Member 000 0000
Oleg Nodelman EcoR1 Capital Board Member 000 0000
Peter Thompson ReCode Therapeutics Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

ReCode Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ReCode Therapeutics Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
EcoR1 Capital Hedge Fund Minority 000 0000 000000 0
NS Investment Corporate Venture Capital Minority 000 0000 000000 0
Pfizer Ventures Corporate Venture Capital Minority 000 0000 000000 0
Sanofi Ventures Corporate Venture Capital Minority 000 0000 000000 0
Superstring Capital Management Hedge Fund Minority 000 0000 000000 0
You’re viewing 5 of 14 investors. Get the full list »

ReCode Therapeutics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000000 06-Mar-2020 000000000000000000 0000 Biotechnology
To view ReCode Therapeutics’s complete acquisitions history, request access »